Proposed Data Collections Submitted for Public Comment and Recommendations, 28938-28939 [E9-14312]
Download as PDF
<![CDATA[
28938
Federal Register / Vol. 74, No. 116 / Thursday, June 18, 2009 / Notices
DATES: Submit written comments on the
collection of information by July 20,
2009.
ADDRESSES: Submit written comments
on the collection of information by fax
202.395.6974 to the OMB Desk Officer
for AoA, Office of Information and
Regulatory Affairs, OMB.
FOR FURTHER INFORMATION CONTACT:
Yvonne Jackson; Director; Office for
American Indian, Alaskan Native and
Native Hawaiian Programs;
Administration on Aging; Washington,
DC, 20201; (202) 357–3501;
Yvonne.Jackson@aoa.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, AoA
has submitted the following proposed
collection of information to OMB for
review and clearance. AoA is requesting
a continuation of an existing collection
for Annual Program Performance
Reports for Older Americans Act Title
VI grantees. Information from the Title
VI Program Performance Report
provides a data base for AoA to (1)
monitor program achievement of
performance objectives; (2) establish
program policy and direction; and (3)
prepare responses to Congress, the
OMB, the U.S. Government
Accountability Office, other federal
departments, and public and private
agencies as required by the OAA Title
II sections 202(a)19 and 208; and (4)
prepare data for the Federal Interagency
Task Force on Older Indians established
pursuant to section 134(d) of the 1987
Amendments to the OAA. If AoA did
not collect the program data herein
requested, it would not be able to
monitor and manage total program
progress as expected, nor develop
program policy options directed toward
assuring the most effective use of
limited Title VI funds. Reports are due
annually on June 30th. AoA submits an
annual report to Congress and the
reporting data is included in that report.
Estimated Number of Responses: 246.
Total Estimated Burden Hours: 615.
In the Federal Register of April 8,
2009 (Vol. 74, No. 66, Pages 15984–
15985), the agency requested comments
on the proposed collection of
information. No comments were
received.
Dated: June 12, 2009.
Edwin L. Walker,
Acting Assistant Secretary for Aging.
[FR Doc. E9–14348 Filed 6–17–09; 8:45 am]
BILLING CODE 4154–01–P
VerDate Nov<24>2008
21:58 Jun 17, 2009
Jkt 217001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day–09–0595]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects.
Alternatively, to obtain a copy of the
data collection plans and instrument,
call 404–639–5960 and send comments
to Maryam I. Daneshvar, CDC Reports
Clearance Officer, 1600 Clifton Road
NE., MS–D74, Atlanta, Georgia 30333;
comments may also be sent by e-mail to
omb@cdc.gov.
Comments are invited on (a) whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarify of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of information technology. Written
comments should be received within 60
days of this notice.
Proposed Project
The Model Performance Evaluation
Program for HIV Rapid Testing (MPEP
HIV–RT) (OMB Control No. 0920–0595,
expiration date 3/31/2010)—Revision—
National Center for Preparedness,
Detection, and Control of Infectious
Diseases (NCPDCID), Centers for Disease
Control and Prevention (CDC).
Brief Description and Background
To support CDC’s mission of
improving public health and preventing
disease through continuously improving
laboratory practices, CDC is requesting
approval from the Office of Management
and Budget (OMB) to continue data
collection activities of the HIV rapid
testing performance evaluation program
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
(MPEP HIV RT) and to make changes to
the results form.
This program offers external
performance evaluation (PE) twice a
year for rapid HIV tests approved by the
U.S. Food and Drug Administration
(FDA). Examples of such tests are the
OraQuick ADVANCE Rapid HIV–1⁄2
Antibody Test, the Uni-Gold
Recombigen HIV test, the Clearview HIV
1⁄2 STAT–PAK, the Clearview
COMPLETE HIV 1⁄2, and the MedMira
Reveal G3 Rapid HIV–1 Antibody Test.
Participation in PE programs is expected
to lead to improved HIV testing
performance because participants have
the opportunity to identify areas for
improvement in their testing practices.
This program helps to ensure accurate
HIV rapid testing which is the
foundation for HIV prevention and
intervention programs.
This program offers laboratories/
testing sites opportunities for:
(1) Assuring that the laboratories/
testing sites are providing accurate test
results through external quality
assessment
(2) Improving testing quality through
self-evaluation in a non-regulatory
environment
(3) Testing well characterized samples
from a source outside the test kit
manufacturer
(4) Discovering potential testing
problems so that laboratories/testing
sites can adjust procedures to reduce
and eliminate errors
(5) Comparing individual laboratory/
testing site results to others at the
national and international level, and
(6) Consulting with CDC staff to
discuss testing issues.
Program participants receive PE
samples twice each year and report
testing results to CDC. In addition to
conducting the performance evaluation,
participants in the MPEP HIV Rapid
Testing program are required to
complete a biennial (every other year)
laboratory practices questionnaire. The
burden for the Laboratory Practices
Questionnaire has been adjusted for the
average per year, since respondents
complete the survey every two years.
CDC does not charge any fees to sites
participating in this external quality
assessment program.
There is no cost to respondents to
participate in this program.
E:\FR\FM\18JNN1.SGM
18JNN1
28939
Federal Register / Vol. 74, No. 116 / Thursday, June 18, 2009 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Average burden per response (in
hours)
Number
of respondents
Number of responses per
respondent
Labs .................................................................................................................
Labs .................................................................................................................
660
330
2
1
10/60
30/60
220
165
Total ..........................................................................................................
........................
........................
........................
385
Respondents
Dated: June 11, 2009.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. E9–14312 Filed 6–17–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day-09–0600]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects.
Alternatively, to obtain a copy of the
data collection plans and instrument,
call 404–639–5960 and send comments
to Maryam I. Daneshvar, CDC Reports
Clearance Officer, 1600 Clifton Road,
NE., MS–D74, Atlanta, Georgia 30333;
comments may also be sent by e-mail to
omb@cdc.gov.
Comments are invited on (a) whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have a
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarify of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of information technology. Written
comments should be received within 60
days of this notice.
VerDate Nov<24>2008
21:58 Jun 17, 2009
Jkt 217001
Proposed Project
Model Performance Evaluation
Program for Mycobacterium tuberculosis
and Non-tuberculous Mycobacterium
Drug Susceptibility Testing (OMB
Control No. 0920–0600, expiration date
03/31/2010)—Revision—National
Center for Preparedness, Detection, and
Control of Infectious Diseases
(NCPDCID), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
As part of the continuing effort to
support both domestic and global public
health objectives for treatment of
tuberculosis (TB), prevention of multidrug resistance, and surveillance
programs, CDC is requesting approval
from the Office of Management and
Budget to continue data collection from
participants in the Model Performance
Evaluation Program for Mycobacterium
tuberculosis and Non-tuberculous
Mycobacterium Drug Susceptibility
Testing. This request includes changes
to the Results Form and re-introduction
of the Laboratory Practices
Questionnaire.
While the overall number of cases of
TB in the U.S. has decreased, rates still
remain high among foreign-born
persons, prisoners, homeless
populations, and individuals infected
with HIV in major metropolitan areas.
The rate of TB cases detected in foreignborn persons has been reported to be
more than nine times higher than the
rate among the U.S. born population.
CDC’s goal to eliminate TB will be
virtually impossible without
considerable effort in assisting heavy
disease burden countries in the
reduction of tuberculosis. The Model
Performance Evaluation Program for
Mycobacterium tuberculosis and Nontuberculous Mycobacterium Drug
Susceptibility Testing program supports
this role by monitoring and evaluating
the level of performance and practices
among national and international
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Total burden
(in hours)
laboratories performing M. tuberculosis
susceptibility testing. Participation in
this program is one way laboratories can
ensure high-quality laboratory testing,
resulting in accurate and reliable testing
results.
By providing an evaluation program
to assess the ability of the laboratories
to test for drug resistant M. tuberculosis
and selected strains of Non-tuberculous
Mycobacteria (NTM), laboratories also
have a self-assessment tool to aid in
optimizing their skills in susceptibility
testing. The information obtained from
laboratories on susceptibility testing
practices and procedures is used to
establish variables related to good
performance, assessing training needs,
and aid with the development of
practice standards.
Participants in this program include
domestic clinical and public health
laboratories and international
laboratories. Data collection from
domestic laboratory participants occurs
twice per year. Data collection from
international laboratories is limited to
those that have public health
responsibilities for tuberculosis drug
susceptibility testing and have obtained
approval to participate by their national
tuberculosis program. The data
collected in this program will include
the susceptibility test results of primary
and secondary drugs, drug
concentrations, and test methods
performed by laboratories on a set of
performance evaluation (PE) samples.
The PE samples are sent to participants
twice a year. Participants also report
demographic data such as laboratory
type and the number of tests performed
annually. Participants report this data
every two years. The burden for the
Laboratory Practices Questionnaire has
been adjusted for the average per year,
since responses are received every other
year.
There is no cost to respondents to
participate other than their time.
E:\FR\FM\18JNN1.SGM
18JNN1
]]>Agencies
[Federal Register Volume 74, Number 116 (Thursday, June 18, 2009)]
[Notices]
[Pages 28938-28939]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-14312]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-09-0595]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
Alternatively, to obtain a copy of the data collection plans and
instrument, call 404-639-5960 and send comments to Maryam I. Daneshvar,
CDC Reports Clearance Officer, 1600 Clifton Road NE., MS-D74, Atlanta,
Georgia 30333; comments may also be sent by e-mail to omb@cdc.gov.
Comments are invited on (a) whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarify of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of information technology. Written comments
should be received within 60 days of this notice.
Proposed Project
The Model Performance Evaluation Program for HIV Rapid Testing
(MPEP HIV-RT) (OMB Control No. 0920-0595, expiration date 3/31/2010)--
Revision--National Center for Preparedness, Detection, and Control of
Infectious Diseases (NCPDCID), Centers for Disease Control and
Prevention (CDC).
Brief Description and Background
To support CDC's mission of improving public health and preventing
disease through continuously improving laboratory practices, CDC is
requesting approval from the Office of Management and Budget (OMB) to
continue data collection activities of the HIV rapid testing
performance evaluation program (MPEP HIV RT) and to make changes to the
results form.
This program offers external performance evaluation (PE) twice a
year for rapid HIV tests approved by the U.S. Food and Drug
Administration (FDA). Examples of such tests are the OraQuick ADVANCE
Rapid HIV-\1/2\ Antibody Test, the Uni-Gold Recombigen HIV test, the
Clearview HIV \1/2\ STAT-PAK, the Clearview COMPLETE HIV \1/2\, and the
MedMira Reveal G3 Rapid HIV-1 Antibody Test. Participation in PE
programs is expected to lead to improved HIV testing performance
because participants have the opportunity to identify areas for
improvement in their testing practices. This program helps to ensure
accurate HIV rapid testing which is the foundation for HIV prevention
and intervention programs.
This program offers laboratories/testing sites opportunities for:
(1) Assuring that the laboratories/testing sites are providing
accurate test results through external quality assessment
(2) Improving testing quality through self-evaluation in a non-
regulatory environment
(3) Testing well characterized samples from a source outside the
test kit manufacturer
(4) Discovering potential testing problems so that laboratories/
testing sites can adjust procedures to reduce and eliminate errors
(5) Comparing individual laboratory/testing site results to others
at the national and international level, and
(6) Consulting with CDC staff to discuss testing issues.
Program participants receive PE samples twice each year and report
testing results to CDC. In addition to conducting the performance
evaluation, participants in the MPEP HIV Rapid Testing program are
required to complete a biennial (every other year) laboratory practices
questionnaire. The burden for the Laboratory Practices Questionnaire
has been adjusted for the average per year, since respondents complete
the survey every two years. CDC does not charge any fees to sites
participating in this external quality assessment program.
There is no cost to respondents to participate in this program.
[[Page 28939]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondents Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Labs............................................ 660 2 10/60 220
Labs............................................ 330 1 30/60 165
---------------------------------------------------------------
Total....................................... .............. .............. .............. 385
----------------------------------------------------------------------------------------------------------------
Dated: June 11, 2009.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E9-14312 Filed 6-17-09; 8:45 am]
BILLING CODE 4163-18-P
